drugset
Drugs / LX1001
last change Nov 2024 re-read 3 minutes ago

LX1001

Gene therapy (AAV / viral vector) targets APOE

Developed for
Alzheimer disease
Investigated by
Lexeo Therapeutics · Alzheimer's Drug Discovery Foundation · Weill Medical College of Cornell University

Trials 2

today NCT05400330 · Ph 1 NCT03634007 · Ph 1/2
2020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT05400330 May 2023 → Nov 2028 expected Alzheimer disease Lexeo Therapeutics Active not recruiting No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT03634007 Nov 2019 → Nov 2024 Alzheimer disease Lexeo Therapeutics Completed No outcome recorded

News releases announcing trial results or a regulatory action · 4

DateIssuerRelease
2024-10-30 Lexeo Therapeutics Results Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference lexeotx.com ↗
Treatment with LX1001 led to dose-dependent increases in APOE2 protein expression and improvements in AD-associated tau biomarkers, measures which have been closely correlated with cognitive outcomes.
2022-03-02 Lexeo Therapeutics Results LEXEO Therapeutics Announces Positive Initial Data from Ongoing Phase 1/2 Clinical Trial of AAV-based Gene Therapy Candidate LX1001 in Patients with Alzheimer’s Disease lexeotx.com ↗
2021-04-28 Lexeo Therapeutics Results LEXEO Therapeutics Announces Upcoming Data Presentations at the American Society of Gene and Cell Therapy (ASGCT) 2021 Virtual Annual Meeting lexeotx.com ↗
Data on second generation investigational gene therapy demonstrate ability to silence the APOE4 gene for the potential treatment of Alzheimer’s disease
2021-04-20 Lexeo Therapeutics Regulatory LEXEO Therapeutics Announces FDA Fast Track Designation Granted to LX1001 for the Treatment of APOE4 Associated Alzheimer’s Disease lexeotx.com ↗

All press releases naming this drug 6 releases

DateIssuerRelease

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as LX1001 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03634007 ↗
1

NCT05400330 ↗
Modality Gene therapy (AAV / viral vector) “LX1001 is a serotype rh.10 AAV gene transfer vector” NCT03634007 ↗
Route Intrathecal “intrathecal administration of AAVrh.10hAPOE2 (LX1001)” NCT03634007 ↗
Target APOE “LX1001 is a serotype rh.10 AAV gene transfer vector expressing the cDNA coding for human APOE2.” NCT03634007 ↗